Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Dec;5(2):131-143.
doi: 10.1007/s40120-016-0052-6. Epub 2016 Sep 17.

Multiple Sclerosis in Pediatrics: Current Concepts and Treatment Options

Affiliations
Review

Multiple Sclerosis in Pediatrics: Current Concepts and Treatment Options

Jasna Jancic et al. Neurol Ther. 2016 Dec.

Abstract

Multiple sclerosis (MS) is a chronic, autoimmune, inflammatory, demyelinating disease of the central nervous system. MS is increasingly recognized in the pediatric population, and it is usually diagnosed around 15 years of age. The exact etiology of MS is still not known, although autoimmune, genetic, and environmental factors play important roles in its development, making it a multifactorial disease. The disease in children almost always presents in the relapsing-remittent form. The therapy involves treatment of relapses, and immunomodulatory and symptomatic treatment. The treatment of children with MS has to be multidisciplinary and include pediatric neurologists, ophthalmologists, psychologists, physiotherapists, and if necessary, pediatric psychiatrists and pharmacologists. The basis of MS therapy should rely on drugs that are able to modify the course of the disease, i.e. immunomodulatory drugs. These drugs can be subdivided into two general categories: first-line immunomodulatory therapy (interferon beta-1a, interferon beta-1b, glatiramer acetate) and second-line immunomodulatory therapy (natalizumab, mitoxantrone, fingolimod, teriflunomide, azathioprine, rituximab, dimethyl fumarate, daclizumab). Treatment of relapses involves the use of high intravenous doses of corticosteroids, administration of intravenous immunoglobulins, and plasmapheresis. We summarize here the current available information related to the etiology and treatment options in MS. Early administration of immunomodulatory therapy is beneficial in adults, while more studies are needed to prove their effectiveness in pediatric populations. Therefore, pediatric MS still represents a great challenge for both, the early and correct diagnosis, as well as its treatment.

Keywords: Etiology; Immunomodulatory therapy; Multiple sclerosis; Pediatrics; Treatment.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Differential diagnosis of multiple sclerosis
Fig. 2
Fig. 2
Diagnostic criteria for adult and pediatric MS [magnetic resonance imaging (MRI), central nervous system (CNS), acute disseminated encephalomyelitis (ADEM), dissemination in space (DIS), dissemination in time (DIT)]

References

    1. Pena JA, Lotze TE. Pediatric multiple sclerosis: current concepts and consensus definitions. Autoimmune Dis. 2013;2013:673947. - PMC - PubMed
    1. Chitnis T. Disease-modifying therapy of pediatric multiple sclerosis. Neurotherapeutics. 2013;10(1):89–96. doi: 10.1007/s13311-012-0158-1. - DOI - PMC - PubMed
    1. Patel Y, Bhise V, Krupp L. Pediatric multiple sclerosis. Ann Indian Acad Neurol. 2009;12(4):238–245. doi: 10.4103/0972-2327.58281. - DOI - PMC - PubMed
    1. Compston A. The 150th anniversary of the first depiction of the lesions of multiple sclerosis. J Neurol Neurosurg Psychiatry. 1988;51(10):1249–1252. doi: 10.1136/jnnp.51.10.1249. - DOI - PMC - PubMed
    1. Orrell RW. Multiple sclerosis: the history of a disease. J R Soc Med. 2005;98(6):289. doi: 10.1258/jrsm.98.6.289. - DOI

LinkOut - more resources